Concord Biotech shares list at 21% premium; surge up to 26% post debut
Post listing, Concord Biotech shares gained 26.2% to hit a high of ₹934.90 on the BSE, while it touched a high of ₹925.90 on the NSE, up 25% against the IPO price.
Post listing, Concord Biotech shares gained 26.2% to hit a high of ₹934.90 on the BSE, while it touched a high of ₹925.90 on the NSE, up 25% against the IPO price.